New inhibitors of HIV latency reactivation
Ended Project Grant Awarded Last action
- Award ID
- R41AI152860
- Recipient
-
Ithax Pharmaceuticals Inc. UEI D6ZLMK2SMHJ5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,183,323
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $884,966.09 Federal
- $298,357.00 Non-federal
- Place of performance
- Shoreline, WA 98133, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$10,158 | $0 | |
| Amendment | $298,357 | $0 | |
| Amendment | $298,357 | $298,357 | |
| Original award | $298,410 | $0 |
Quick answers
Who received award R41AI152860?
R41AI152860 was awarded to Ithax Pharmaceuticals Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 2, 2020.
How much is award R41AI152860 worth?
$1,183,323 has been obligated on R41AI152860: $884,966 in federal funding and $298,357 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award